Loading...
Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The last earnings update was 92 days ago. More info.
7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
---|---|---|---|---|---|---|
Atossa Genetics (ATOS) | -4.9% | 28.3% | 32.5% | -80.5% | -98.2% | -99.6% |
US Medical Equipment | 2.6% | 8.9% | 7.3% | 22% | 73.9% | 89.5% |
US Market | 0.5% | 6.3% | 1.9% | 2% | 45.1% | 40.5% |
Data Point | Source | Value |
---|---|---|
Earnings Per Share * | Company Filings (2018-09-30) in USD | $-7.09 |
NasdaqCM:ATOS Share Price ** | NasdaqCM (2019-02-13) in USD | $1.62 |
United States of America Medical Equipment Industry PE Ratio | Median Figure of 62 Publicly-Listed Medical Equipment Companies | 47.35x |
United States of America Market PE Ratio | Median Figure of 3,046 Publicly-Listed Companies | 16.95x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Atossa Genetics.
Calculation | Outcome | |
---|---|---|
PE Ratio | = NasdaqCM:ATOS Share Price ÷ EPS (both in USD) = 1.62 ÷ -7.09 |
-0.23x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Data Point | Source | Value |
---|---|---|
PE Ratio | See PE Ratio Section | -0.23x |
Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts |
52.9%per year |
United States of America Medical Equipment Industry PEG Ratio | Median Figure of 53 Publicly-Listed Medical Equipment Companies | 2.62x |
United States of America Market PEG Ratio | Median Figure of 2,117 Publicly-Listed Companies | 1.36x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Data Point | Source | Value |
---|---|---|
Book Value per Share | Company Filings (2018-09-30) in USD | $1.28 |
NasdaqCM:ATOS Share Price * | NasdaqCM (2019-02-13) in USD | $1.62 |
United States of America Medical Equipment Industry PB Ratio | Median Figure of 185 Publicly-Listed Medical Equipment Companies | 4.14x |
United States of America Market PB Ratio | Median Figure of 5,122 Publicly-Listed Companies | 1.81x |
Calculation | Outcome | |
---|---|---|
PB Ratio | = NasdaqCM:ATOS Share Price ÷ Book Value per Share (both in USD) = 1.62 ÷ 1.28 |
1.27x |
* Primary Listing of Atossa Genetics.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Data Point | Source | Value (per year) |
---|---|---|
NasdaqCM:ATOS Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts | 52.9% |
United States of America Medical Equipment Industry Earnings Growth Rate | Market Cap Weighted Average | 21.3% |
United States of America Medical Equipment Industry Revenue Growth Rate | Market Cap Weighted Average | 7.4% |
United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.4% |
United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.1% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Data Point | Source | Value |
---|---|---|
Past Financials | Company Filings (4 months ago) | See Below |
Future Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
---|---|---|---|---|
2023-12-31 | 107 | 47 | 1 | |
2022-12-31 | 75 | 27 | 1 | |
2021-12-31 | 38 | 3 | 1 | |
2020-12-31 | 1 | -17 | 3 | |
2019-12-31 | 0 | -17 | 3 | |
2018-12-31 | 0 | -18 | 3 |
Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
---|---|---|---|
2018-09-30 | -8 | -23 | |
2018-06-30 | -8 | -22 | |
2018-03-31 | -7 | -11 | |
2017-12-31 | -7 | -11 | |
2017-09-30 | -6 | -11 | |
2017-06-30 | -4 | -9 | |
2017-03-31 | -4 | -6 | |
2016-12-31 | -5 | -6 | |
2016-09-30 | 0 | -8 | -6 |
2016-06-30 | 0 | -12 | -10 |
2016-03-31 | 0 | -14 | -12 |
2015-12-31 | 0 | -14 | -13 |
*GAAP earnings excluding extraordinary items.
Data Point | Source | Value |
---|---|---|
Past Financials | Company Filings (4 months ago) | See Below |
Future Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
All data from Atossa Genetics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
---|---|---|---|---|
2023-12-31 | 2.82 | 2.82 | 2.82 | 1.00 |
2022-12-31 | 1.65 | 1.65 | 1.65 | 1.00 |
2021-12-31 | 0.23 | 0.23 | 0.23 | 1.00 |
2020-12-31 | -1.47 | -0.97 | -1.97 | 2.00 |
2019-12-31 | -2.51 | -1.88 | -2.84 | 3.00 |
2018-12-31 | -5.03 | -4.31 | -5.94 | 3.00 |
Date (Data in USD Millions) | EPS * |
---|---|
2018-09-30 | -7.09 |
2018-06-30 | -9.98 |
2018-03-31 | -6.97 |
2017-12-31 | -10.97 |
2017-09-30 | -19.62 |
2017-06-30 | -23.42 |
2017-03-31 | -20.90 |
2016-12-31 | -25.93 |
2016-09-30 | -29.65 |
2016-06-30 | -54.85 |
2016-03-31 | -68.29 |
2015-12-31 | -80.78 |
*GAAP earnings excluding extraordinary items.
How has Atossa Genetics performed over the past 5 years?
All data from Atossa Genetics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
---|---|---|---|---|
2018-09-30 | -22.80 | 7.28 | 3.58 | |
2018-06-30 | -21.67 | 6.71 | 2.90 | |
2018-03-31 | -10.86 | 5.10 | 2.25 | |
2017-12-31 | -10.69 | 4.86 | 2.33 | |
2017-09-30 | -11.22 | 4.98 | 2.48 | |
2017-06-30 | -8.83 | 4.98 | 1.82 | |
2017-03-31 | -5.74 | 5.46 | 1.16 | |
2016-12-31 | -6.37 | 6.48 | 0.77 | |
2016-09-30 | 0.00 | -6.44 | 6.91 | 0.88 |
2016-06-30 | 0.00 | -10.41 | 8.50 | 1.74 |
2016-03-31 | 0.00 | -11.81 | 9.74 | 1.94 |
2015-12-31 | 0.00 | -12.76 | 10.27 | 2.36 |
2015-09-30 | 0.00 | -13.49 | 10.12 | 1.14 |
2015-06-30 | 0.01 | -12.97 | 9.55 | 1.12 |
2015-03-31 | 0.02 | -13.03 | 9.44 | 1.25 |
2014-12-31 | 0.04 | -12.17 | 8.75 | 1.11 |
2014-09-30 | 0.08 | -11.60 | 9.49 | 2.02 |
2014-06-30 | 0.16 | -11.86 | 10.39 | 1.41 |
2014-03-31 | 0.47 | -11.25 | 10.25 | 1.09 |
2013-12-31 | 0.63 | -10.78 | 10.03 | 0.89 |
2013-09-30 | 0.68 | -9.73 | 8.86 | 1.15 |
2013-06-30 | 0.71 | -7.37 | 6.31 | 1.37 |
2013-03-31 | 0.61 | -5.96 | 4.59 | 1.77 |
2012-12-31 | 0.48 | -5.08 | 3.48 | 1.92 |
2012-09-30 | 0.38 | -4.58 | 3.21 | 1.51 |
2012-06-30 | 0.28 | -4.66 | 3.76 | 0.96 |
2012-03-31 | 0.06 | -4.27 | 3.73 | 0.37 |
*GAAP earnings excluding extraordinary items.
How is Atossa Genetics's financial health and their level of debt?
All data from Atossa Genetics Company Filings, last reported 4 months ago.
Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
---|---|---|---|
2018-09-30 | 10.57 | 0.00 | 12.94 |
2018-06-30 | 13.57 | 0.00 | 15.24 |
2018-03-31 | 5.26 | 0.00 | 4.78 |
2017-12-31 | 6.94 | 0.00 | 7.22 |
2017-09-30 | 2.56 | 0.00 | 2.73 |
2017-06-30 | 2.80 | 0.00 | 3.69 |
2017-03-31 | 1.53 | 0.00 | 1.17 |
2016-12-31 | 3.10 | 0.00 | 3.03 |
2016-09-30 | 5.41 | 0.00 | 4.39 |
2016-06-30 | 2.41 | 0.00 | 1.19 |
2016-03-31 | 3.77 | 0.00 | 2.88 |
2015-12-31 | 3.74 | 0.00 | 3.72 |
2015-09-30 | 9.06 | 0.00 | 7.84 |
2015-06-30 | 13.12 | 0.08 | 11.40 |
2015-03-31 | 10.28 | 0.11 | 9.73 |
2014-12-31 | 9.50 | 0.00 | 8.50 |
2014-09-30 | 15.23 | 0.00 | 11.37 |
2014-06-30 | 18.26 | 0.00 | 14.30 |
2014-03-31 | 21.30 | 0.00 | 16.59 |
2013-12-31 | 10.60 | 0.02 | 6.34 |
2013-09-30 | 11.54 | 0.00 | 7.69 |
2013-06-30 | 8.28 | 0.00 | 2.44 |
2013-03-31 | 6.98 | 0.00 | 1.39 |
2012-12-31 | 5.18 | 0.00 | 1.73 |
2012-09-30 | 3.40 | 0.33 | 0.42 |
2012-06-30 | -0.56 | 0.25 | 0.09 |
2012-03-31 | 0.59 | 0.25 | 0.90 |
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
What is Atossa Genetics's current dividend yield, its reliability and sustainability?
Data Point | Source | Value |
---|---|---|
Past Annualized Dividend Yield | S&P Global Market Data | See Below |
Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
Future Dividends per Share Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
United States of America Medical Equipment Industry Average Dividend Yield | Market Cap Weighted Average of 23 Stocks | 1.3% |
United States of America Market Average Dividend Yield | Market Cap Weighted Average of 1997 Stocks | 2.5% |
United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
United States of America Top 25% Dividend Yield | 75th Percentile | 3.6% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
---|---|---|
2023-12-31 | ||
2022-12-31 | ||
2021-12-31 | ||
2020-12-31 | ||
2019-12-31 | 0.00 | 1.00 |
2018-12-31 | 0.00 | 1.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Dr. Steven C. Quay, also known as Steve, M.D., Ph.D., FCAP has been the Chief Executive Officer and President of Atossa Genetics, Inc. since April 30, 2009 and served as its Chief Financial Officer since April 30, 2009. Dr. Quay also served as Treasurer of Atossa Genetics, Inc. and served as its Corporate Secretary and Chief Accounting Officer. He served as the Chief Scientific Officer of MDRNA, Inc. from June 23, 2008 to November 30, 2008. Dr. Quay served as the Chief Executive Officer of MDRNA, Inc. from August 2000 to June 23, 2008 and also served as its President from August 2000 to December 20, 2007. He served as the Chief Executive Officer of Nycomed Salutar, Inc. He founded Atossa Healthcare Inc. in 1999 and Salutar, Inc. in 1984. Dr. Quay served as the Chairman of the Board, President and Chief Executive Officer of Atossa Healthcare Inc. Dr. Quay Founded SONUS Pharmaceuticals, Inc., in 1991 where he served as Chief Executive Officer, President and a Director until June 1999. Dr. Quay serves as Chairman of Atossa Genetics, Inc. Dr. Quay served as Chairman of the Board of MDRNA, Inc. from August 2000 to November 30, 2008. He served as Chairman of the Scientific Advisory Board of MDRNA, Inc. from June 23, 2008 to November 30, 2008. Dr. Quay has been a Director of Atossa Genetics, Inc. since April 30, 2009. Dr. Quay serves as a Director of VitalMedix Inc. Dr. Quay served as Director of MDRNA, Inc. from August 2000 to May 20, 2009 and its Member of the Scientific Advisory Board from June 23, 2008 to May 20, 2009. From 1980 to 1986, he served as a Faculty Member at Stanford University School of Medicine. Dr. Quay serves as a Member of numerous professional societies, including the American Medical Association, the American Society for Biochemistry and Molecular biology, the Society of Magnetic Resonance in Medicine, the American Society for Echo cardiology and the American Institute for Ultrasound Medicine. He has 135 scientific publications, 67 patents and is a board-certified pathologist. Dr. Quay graduated from the University of Michigan Medical School, where he received an M.D., M.A. and Ph.D. in Biological Chemistry in 1977, 1974 and 1975, respectively. Dr. Quay did Post-Graduate work in the Chemistry department at the Massachusetts Institute of Technology and received his Residency training at the Massachusetts General Hospital, Harvard Medical School. He holds BA in Chemistry and mathematics from Michigan University.
Average tenure of the Atossa Genetics management team in years:
Average tenure and age of the Atossa Genetics board of directors in years:
Atossa Genetics Inc (NASDAQ:ATOS), a medical equipment company based in United States,. … As a small cap stock, which tends to lack high analyst coverage, there is generally more of an opportunity for mispricing as there is less activity to push the stock closer to fair value? … Let’s examine Atossa Genetics’s valuation and outlook in more detail to determine if there’s still a bargain opportunity
Simply Wall St - – Full articleAtossa Genetics Inc's (NASDAQ:ATOS):. … The US$7.60m market-cap posted a loss in its most recent financial year of -US$10.69m and a latest trailing-twelve-month loss of -US$10.86m leading to an even wider gap between loss and breakeven? … In this article, I will touch on the expectations for ATOS’s growth and when analysts expect the company to become profitable
Simply Wall St - – Full articleIn this article, I will touch on the expectations for ATOS’s growth and when analysts expect the company to become profitable. … NasdaqCM:ATOS Past Future Earnings May 17th 18 Given this is a high-level overview, I won’t go into detail the detail of ATOS’s upcoming projects, though, keep in mind that typically a high forecast growth rate is not unusual for a company that is currently undergoing an investment period. … ATOS currently has no debt on its balance sheet, which is quite unusual for a cash-burning loss-making, growth company, which usually has a high level of debt relative to its equity.
Simply Wall St - – Full articleNasdaqCM:ATOS Income Statement Apr 25th 18 We can further analyze Atossa Genetics's loss by looking at what the industry has been experiencing over the past few years. … This shows that any tailwind the industry is profiting from, Atossa Genetics has not been able to reap as much as its industry peers.What does this mean? … You should continue to research Atossa Genetics to get a more holistic view of the stock by looking at: Future Outlook: What are well-informed industry analysts predicting for ATOS’s future growth?
Simply Wall St - – Full articleIn December 2017, Atossa Genetics Inc (NASDAQ:ATOS) released its latest earnings announcement, which suggested company earnings became less negative compared to the previous year's level - great news for investors Below, I've presented key growth figures on how market analysts perceive Atossa Genetics's earnings growth outlook over the next few years and whether the future looks brighter. … Check out our latest analysis for Atossa Genetics Market analysts' consensus outlook for next year seems relatively subdued, with earnings continuing to flop around in the negative territory, reaching -US$10.67M in 2019. … This means that, we can assume Atossa Genetics will grow its earnings by 25.97% every year for the next few years.
Simply Wall St - – Full articleLet’s take a look at Atossa Genetics’s outlook and value based on the most recent financial data to see if the opportunity still exists. … Great news for investors – Atossa Genetics is still trading at a fairly cheap price. … What’s more interesting is that, Atossa Genetics’s share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future.
Simply Wall St - – Full articleThis size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … Thus, investors not need worry too much about the consequences of these holdings.Next Steps: While institutional ownership in ATOS is low, active hedge funds still have a significant stake in the company.
Simply Wall St - – Full articleNasdaqCM:ATOS Income Statement Jan 31st 18 When will Atossa Genetics need to raise more cash? … In Atossa Genetics’s case, its opex fell by 1.33% last year, which may signal the company moving towards a more sustainable level of expenses. … However, even with declining costs, the current level of cash is not enough to sustain Atossa Genetics’s operations and the company may need to come to market to raise more capital within the year.
Simply Wall St - – Full articleBased on this beta value, ATOS may be a stock for investors with a portfolio mainly made up of low-beta stocks. … ATOS, with its market capitalisation of $10.35M, is a small-cap stock, which generally have higher beta than similar companies of larger size. … Thus, we can expect ATOS to be more stable in the face of market movements, relative to its peers of similar size but with a higher portion of fixed assets on their books.
Simply Wall St - – Full articleView our latest analysis for Atossa Genetics Did Quay create value? … ATOS can create value to shareholders by increasing its profitability, which in turn is reflected into the share price and the investor's ability to sell their shares at higher capital gains. … To research more about these fundamentals, I recommend you check out our simple infographic report on ATOS's financial metrics.
Simply Wall St - – Full article
Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.
Name: | Atossa Genetics Inc. |
ATOS | |
Exchange: | NasdaqCM |
Founded: | 2009 |
$9,129,909 | |
5,646,552 | |
Website: | http://www.atossagenetics.com |
Address: |
Atossa Genetics Inc. 107 Spring Street, Seattle, Washington, 98104, United States |
Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
---|---|---|---|---|---|---|---|
NasdaqCM | ATOS | Common Stock | Nasdaq Capital Market | US | USD | 08. Nov 2012 | |
DB | YAG2 | Common Stock | Deutsche Boerse AG | DE | EUR | 08. Nov 2012 | |
BST | YAG2 | Common Stock | Boerse-Stuttgart | DE | EUR | 08. Nov 2012 |
Health Care Equipment | |
Healthcare |
Area | Date (UTC time) |
---|---|
Company Analysis updated: | 2019/02/14 00:53 |
End of day share price update: | 2019/02/13 00:00 |
Last estimates confirmation: | 2019/01/24 |
Last earnings filing: | 2018/11/14 |
Last earnings reported: | 2018/09/30 |
Last annual earnings reported: | 2017/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.